Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

The new-generation hormonal agent enzalutamide has been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC), in both post- and predocetaxel setting, due to the significant improvement in overall survival. More recently, enzalutamide also showed impressive results in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tucci, Marcello, Zichi, Clizia, Buttigliero, Consuelo, Vignani, Francesca, Scagliotti, Giorgio V, Di Maio, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204864/
https://www.ncbi.nlm.nih.gov/pubmed/30425524
http://dx.doi.org/10.2147/OTT.S153764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204864/
https://www.ncbi.nlm.nih.gov/pubmed/30425524
http://dx.doi.org/10.2147/OTT.S153764

Ejemplares similares